Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131394 | 0.83 | KDM1A (0.34) | GRM4BACE1KCNH2 | |
| SCHEMBL1129532 | 0.66 | GRM4 (0.34) | GRM4 | |
| SCHEMBL1129687 | 0.64 | DRD2 (0.31) | — | |
| SCHEMBL14264346 | 0.63 | CYP11B1 (0.34) | GRM4 | |
| SCHEMBL31207879 | 0.61 | SIGMAR1 (0.32) | — | |
| SCHEMBL281668 | 0.60 | TMEM97 (0.44) | — | |
| SCHEMBL17729268 | 0.60 | GRM4 (0.36) | GRM4 | |
| SCHEMBL8097676 | 0.60 | GRM4 (0.36) | GRM4 | |
| SCHEMBL320385 | 0.60 | TMEM97 (0.36) | — | |
| SCHEMBL4326313 | 0.60 | CYP3A4 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071774-B2 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| EP-1896481-B1 | HETEROCYCLIC SPIRO-COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-20100010015-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010015-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | REN, NR3C2, CYP21A2 | GRM4 4353/4885BACE1 1643/4885KCNH2 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.